人工智能驱动的药物研发平台Manas AI获得2460万美元种子轮融资，将利用种子资金扩大其人工智能平台规模，拓展全球临床项目，并丰富其候选药物研发管线-动脉网

LinkedIn cofounder launches Manas AI with $24.6M for AI drug discovery

MobiHealthNews 等信源发布 2025-01-27 17:16



可切换为仅中文







Photo: sanjeri/Getty Images

照片：桑杰里/盖蒂图片社

Manas AI, an AI-driven drug discovery platform, has launched with $24.6 million in seed round in a round co-led by General Catalyst and LinkedIn cofounder Reid Hoffman.

Manas AI是一个人工智能驱动的药物发现平台，在General Catalyst和LinkedIn联合创始人里德·霍夫曼（Reid Hoffman）的共同领导下，以2460万美元的种子资金启动了这一轮。

Greylock and other strategic investors participated in the round.

格雷洛克和其他战略投资者参与了这轮谈判。

LinkedIn cofounder Reid Hoffman and Dr. Siddhartha Mukherjee, an oncologist, researcher and author, founded Manas AI.

LinkedIn联合创始人里德·霍夫曼（ReidHoffman）和肿瘤学家、研究员和作家悉达多·穆克吉（SiddharthaMukherjee）博士创立了马纳斯AI。

WHAT IT DOES

它的功能

Manas AI is a drug discovery platform that uses its proprietary AI, biology, generational computational chemistry and advanced molecular docking for drug discovery and development, from identification to clinical trials.

Manas AI是一个药物发现平台，它使用其专有的AI，生物学，世代计算化学和先进的分子对接进行药物发现和开发，从鉴定到临床试验。

The company says its AI 'generates bespoke chemical libraries and utilizes advanced AI filters to identify high-potential therapeutic candidates with paradigm-shifting speed and accuracy.'

该公司表示，其人工智能“生成定制的化学库，并利用先进的人工智能过滤器来识别具有范式转换速度和准确性的高潜力候选治疗药物。”

Through a partnership with Microsoft, Manas AI will use the tech giant's cloud computing platform Azure and its knowledge in AI to identify and develop medicines to accelerate therapeutics for cancer, autoimmune diseases and rare medical conditions.

通过与微软的合作，Manas AI将利用科技巨头的云计算平台Azure及其在AI方面的知识来识别和开发药物，以加速癌症、自身免疫性疾病和罕见疾病的治疗。

Manas AI said it will initially focus on developing treatments for aggressive cancers like prostate cancer, lymphoma and triple-negative breast cancer and eventually move into targeting other diseases.

Manas AI表示，它将首先专注于开发针对前列腺癌、淋巴瘤和三阴性乳腺癌等侵袭性癌症的治疗方法，并最终转向针对其他疾病。

The company will use the seed funding to scale its AI platform, expand its global clinical programs, and enhance its drug candidate pipeline.

该公司将利用种子基金扩大其人工智能平台，扩大其全球临床计划，并加强其候选药物渠道。

'Amidst all the hype in AI-powered drug discovery today, Manas AI is poised to make truly practical, game-changing advances,' Peter Lee, president of Microsoft Research, said in a statement.

。

'It's especially exciting to integrate world-class AI capabilities with groundbreaking chemistry, biology, and wet-lab expertise as we aim to reshape the future of medicine. Microsoft is proud to partner with Manas to help realize this critically important mission.'

“当我们致力于重塑医学的未来时，将世界一流的人工智能能力与开创性的化学、生物学和湿实验室专业知识相结合尤其令人兴奋。微软很自豪能与玛纳斯合作，帮助实现这一至关重要的使命。”

MARKET SNAPSHOT

Scientists have been

科学家已经

laying the groundwork for AI

为人工智能奠定基础

since the 1950s, though recent

自20世纪50年代以来，尽管最近

technological advancements

技术进步

have accelerated the technology's use in

加速了该技术在

drug discovery

药物发现

Last week, a day after his inauguration for his second term, President Trump, alongside

上周，在特朗普总统第二任期就职一天后

Oracle's

Oracle的

chief technology officer Larry Ellison,

首席技术官拉里·埃里森，

OpenAI

CEO Sam Altman and

首席执行官 Sam Altman 和

SoftBank

软银

CEO Masayoshi Son,

CEO Masayoshi Son，

announced Project Stargate

宣布的Stargate项目

, an at least $500 billion investment to build the infrastructure to power AI construction.

，这是一笔至少5000亿美元的投资，用于建设基础设施，为人工智能建设提供动力。

The project includes building 'colossal data centers' and campuses nationwide in America, with one of its goals to enhance cancer detection and personalized vaccines.

该项目包括在美国全国建立“大型数据中心”和校园，其目标之一是加强癌症检测和个性化疫苗。

Ten buildings are currently under construction in Abilene, Texas, each with an area of half a million square feet. Oracle's CTO said the number will expand to 20 buildings and extend beyond Abilene.

德克萨斯州阿比林市目前正在建造10栋建筑，每栋建筑面积50万平方英尺。甲骨文首席技术官表示，这一数字将扩大到20栋建筑，并超出阿比林。

Son said there will be an immediate $100 billion investment in the project with the goal of it becoming $500 billion within the next four years.

Son表示，该项目将立即投资1000亿美元，目标是在未来四年内达到5000亿美元。

Another company in the AI drug discovery space is Israel-based

AI药物发现领域的另一家公司位于以色列

AION Labs

AION 实验室

, which is a partnership between

，即

major pharma companies

主要制药公司

, including

，包括

AstraZeneca

阿斯利康

Merck

默克公司

Pfizer

辉瑞公司

Israel Biotech Fund

以色列生物技术基金

and

和

Teva Pharmaceuticals

Teva 制药

, as well as tech company

，以及科技公司

Amazon Web Services

亚马逊网络服务

and German independent research institute Bio Med X.

和德国独立研究所Bio Med X。

AION, founded in 2021, was built under a government tender with the support of the Israeli government via the Israel Innovation Authority. The venture studio currently has seven companies in its portfolio.

AION成立于2021年，是在以色列政府通过以色列创新管理局（Israel Innovation Authority）的支持下，在政府招标下建造的。该风险投资工作室目前在其投资组合中有七家公司。

Tags:

标签：

Manas AI

马纳斯 AI

AI drug discovery

AI药物发现

drug discovery

药物发现

artificial intelligence

人工智能

More regional news